コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ial aerosol-generating events (eg, coughing, sneezing).
2 ible for eliciting the ciliary response to a sneeze.
3 u of other bacteria/m3/min were released per sneeze.
4 vide a robust tether to withstand coughs and sneezes.
5 roduced via breathing, talking, coughing, or sneezing.
6 y reduced rhinorrhea, nasal obstruction, and sneezing.
7 were nasal stuffiness, nasal discharge, and sneezing.
8 infected ferrets during normal breathing and sneezing.
9 mptoms were nasal stuffiness, discharge, and sneezing.
10 nificant amount of S. aureus into the air by sneezing.
11 sessions with and without histamine-induced sneezing.
12 ng protective reflexes that include apnea or sneezing.
13 n of fever, muscle ache, scratchy throat, or sneezing.
14 plets (aerosols) via exhaling, coughing, and sneezing.
15 n B (NMB) peptide is essential for signaling sneezing.
16 CI 5.02-8.39), hair loss (3.99, 3.63-4.39), sneezing (2.77, 1.40-5.50), ejaculation difficulty (2.63
17 eloped to deliver a stimulation simulating a sneeze (55 mmHg for 50 ms) at 26 degrees C to the apical
18 is, including nasal itching, rhinorrhea, and sneezing, although most agents are not very effective in
21 l steroids led to a significant reduction in sneezes and eosinophil influx in nasal secretions withou
22 ol groups, except for a greater incidence of sneezing and application site reaction (99% mild or mode
26 rotransmission/modulation mechanisms between sneezing and coughing, offering neuronal drug targets fo
28 presence of at least two symptoms: 'repeated sneezing and itchy nose', 'blocked nose for more than on
32 peated BK challenges led to tachyphylaxis of sneezing and of neurally mediated serous glandular secre
33 presence of >/=1 rhinitis symptom (repeated sneezing and/or itchy nose, blocked nose for >1 h, or ru
36 ssociated with symptoms of nasal congestion, sneezing, and itching of the eyes, nose, and throat.
39 nerve evokes protective reflexes, including sneezing, apnea, and local neurogenic inflammation of th
41 ncreased cough, sore throat, runny nose, and sneezing are associated with the emergence of the Omicro
42 ng 3 feet closer, being exposed to coughs or sneezes as 3 to 4 ft closer, greeting with a hug as 7 ft
47 (36.8 versus 24.3 mm; p = 0.003), decreased sneeze clearability (20.6 versus 32 mm; p = 0.04), and i
49 e throat, nasal discharge, nasal congestion, sneezing, cough, scratchy throat, hoarseness, muscle ach
50 treatment period; most were mild, nonocular (sneezing, cough, throat irritation, and instillation sit
51 ease in pressure in the upper airways during sneezing, coughing, or vomiting, which very rarely leads
54 induced clinical symptoms such as coughing, sneezing, decreased activity, fever, and labored breathi
55 d point was defined after excluding the item sneezing due to its low ability to discriminate severity
56 of NMB-sensitive postsynaptic neurons in the sneeze-evoking region or deficiency in NMB receptor abol
58 y events relates to airspeed (speech, cough, sneeze), fluid properties of the saliva/mucus, and the f
60 o interrogate the molecular cascades driving sneeze-induced changes of CBF, pharmacologic manipulatio
61 significant immediate increases in symptoms, sneezes, ipsilateral nasal airway resistance, and ipsila
62 sues involved such symptoms include itching, sneezing, irritation, vasodilation, and reflex secretion
63 sons through exhaling, talking, coughing and sneezing is a major driver of SARS-CoV-2 transmission, w
66 ction occurs but can include red itchy eyes, sneezing, nasal congestion, rhinorrhea, coughing, bronch
67 reatment reduced the severity of rhinorrhea, sneezing, nasal obstruction, sore throat, cough, and hea
69 (SE, 0.3), rhinorrhea of -1.3 (SE, 0.3), and sneeze of -8.8 (SE, 1.5); group 2, itching of -0.6 (SE,
70 (SE, 0.3), rhinorrhea of -0.8 (SE, 0.3), and sneeze of -9.1 (SE, 1.5); and group 3, rhinorrhea of -0.
71 uate the effect of the mechanical force of a sneeze on sinonasal cilia function and determine the mol
72 t of colored dye that approximated a patient sneezing on a dimensionally accurate cardboard slit lamp
73 03), ipratropium was associated with reduced sneezing on study days 2 (20% difference; P = 0.03) and
77 questionnaire: 484 (48.3%) had at least one sneezing, or a runny or blocked nose episodes without co
79 (P = .004), 83% for daily summation operator sneezing (P = .001), 75% for daily summation operator wa
80 y delineates a peptidergic pathway mediating sneezing, providing molecular insights into the sneezing
84 population (MrgprC11(+)MrgprA3(-)) mediates sneezing responses to a multitude of nasal irritants, al
85 nitis was defined as one or more episodes of sneezing, runny and/or blocked nose >2 weeks duration.
88 r, and >/=2 of runny nose, nasal congestion, sneezing, sore throat, cough, swollen or tender neck gla
90 the absence of symptoms such as coughing or sneezing, the importance of speech-generated aerosol in
91 hniques, we mimic the effect of coughing and sneezing, thereby testing the force stability of SARS-Co
94 tostatin [SST(+)]) mediates coughing but not sneezing, unraveling an unforeseen sensory difference be
95 es to catch expelled droplets from coughs or sneezes, use of face masks as appropriate, hand-washing
96 x responses, including expiration, coughing, sneezing, vomiting, postural control, production of spee
100 apidly increases by >/=150% in response to a sneeze, which is dependent on the release of adenosine t
101 tionally emphasized the role of coughing and sneezing, which are dramatic expiratory events that yiel
102 re involved in sinonasal ciliary response to sneezing, which is blunted in patients with upper-airway
103 RA) model for impulse emissions, coughing or sneezing, with aerosolized synthetic DNA tracer concentr
104 uses itching, nasal congestion, and repeated sneezing, with profound effects on quality of life, work